BioCentury
ARTICLE | Financial News

Nabriva raises $50M

April 8, 2015 12:31 AM UTC

Nabriva Therapeutics AG (Vienna, Austria) raised $50 million in the first tranche of a planned $120 million series B round. New investors Vivo Capital and OrbiMed led the round. New investors EcoR1 Capital and Boxer Capital of Tavistock Life Sciences and existing investors HBM Partners; Phase4 Partners; The Wellcome Trust; Global Life Science Ventures; and Novartis Venture Fund also participated.

CEO Collin Broom told BioCentury the syndicate intends to supply a $70 million second tranche when Nabriva requires additional funds to complete its development program. ...